Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH‐HD2002 trial. Issue 3 (14th November 2018)

• Record Type: Journal Article
• Authors: Kurch, L.; Hasenclever, D.; Kluge, R.; Georgi, T.; Tchavdarova, L.; Golombeck, M.; Sabri, O.; Eggert, A.; Brenner, W.; Sykora, K.W.; Bengel, F.M.; Rossig, C.; Körholz, D.; Schäfers, M.; Feuchtinger, T.; Bartenstein, P.; Ammann, R.A.; Krause, T.; Urban, C.; Aigner, R.; Gattenlöhner, S.; Klapper, W.; Mauz‐Körholz, C.
• Is Part Of: Pediatric blood & cancer. Volume 66:Issue 3(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-11-14
• Subjects: F18‐FDG‐PET -- GPOH‐HD2002 trial -- pediatric Hodgkin lymphoma (PHL) -- qPET -- quantitative Deauville score (qDS) -- visual Deauville score (vDS); Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.27539
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Purpose: In 2014, we published the qPET method to quantify fluorodeoxyglucose positron emission tomography (FDG‐PET) responses. Analysis of the distribution of the quantified signals suggested that a clearly abnormal FDG‐PET response corresponds to a visual Deauville score (vDS) of 5 and high qPET values ≥ 2. Evaluation in long‐term outcome data is still pending. Therefore, we analyzed progression‐free survival (PFS) by early FDG‐PET response in a subset of the GPOH‐HD2002 trial for pediatric Hodgkin lymphoma (PHL). Patients/Methods: Pairwise FDG‐PET scans for initial staging and early response assessment after two cycles of chemotherapy were available in 93 PHL patients. vDS and qPET measurement were performed and related to PFS. Results: Patients with a qPET value ≥ 2.0 or vDS of 5 had 5‐year PFS rates of 44%, respectively 50%. Those with qPET values < 2.0 or vDS 1 to 4 had 5‐year PFS rates of 90%, respectively 80%. The positive predictive value of FDG‐PET response assessment increased from 18% (9%; 33%) using a qPET threshold of 0.95 (vDS ≤ 3) to 30% (13%; 54%) for a qPET threshold of 1.3 (vDS ≤ 4) and to 56% (23%; 85%) when the qPET threshold was ≥ 2.0 (vDS 5). The negative predictive values remained stable at ≥92% (CI: 82%; 98%). Conclusion: Only strongly enhanced residual FDG uptake in early response PET (vDS 5 or qPET ≥ 2, respectively) seems to be markedly prognostic in PHL when treatment according to the GPOH‐HD‐2002 protocol is given.